Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | CDK8 | P49336 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | ULK1 | O75385 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613043 | 0.89 | CDK1 (0.39) | KDRCDK8FEN1FGFR1LMNA | |
| SCHEMBL25625569 | 0.86 | FGFR1 (0.35) | KDRCDK8FEN1FGFR1CDK1 | |
| SCHEMBL25613037 | 0.82 | FEN1 (0.39) | KDRCDK8FEN1FGFR1RIPK1 | |
| SCHEMBL25613050 | 0.81 | FEN1 (0.39) | KDRCDK8FEN1FGFR1MAPK1 | |
| SCHEMBL25613036 | 0.79 | FEN1 (0.36) | KDRCDK8FEN1FGFR1CDK1 | |
| SCHEMBL25613035 | 0.78 | ULK1 (0.39) | KDRCDK8FEN1FGFR1LMNA | |
| SCHEMBL25613335 | 0.78 | FEN1 (0.39) | KDRCDK8FEN1FGFR1RIPK1 | |
| SCHEMBL25613045 | 0.78 | ULK1 (0.39) | KDRCDK8FEN1FGFR1LMNA | |
| SCHEMBL25613057 | 0.77 | KDM4E (0.39) | KDRCDK8FEN1FGFR1LMNA | |
| SCHEMBL25613169 | 0.77 | BRD4 (0.40) | KDRCDK8FEN1FGFR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | KDR 465/4885CDK8 533/4885FEN1 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.